A trial comparing a drug called ABP 980 (Kanjinti) with trastuzumab (Herceptin) for HER2 positive breast cancer

This trial compared ABP 980 (Kanjinti) with trastuzumab (Herceptin) in breast cancer that had receptors for the HER2 protein.

Breast cancer with cells that have a lot of HER2 receptors are HER2 positive. This trial was for HER2 positive breast cancer that had not spread elsewhere in the body (early breast cancer).

This trial was open for women to join between 2013 and 2015. These results were published in 2018.